ENLIVEN THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $84.4M | $47.7M |
| FY2021 | — | $-42.9M | $48.3M |
| FY2022 | — | $-76.8M | $75.5M |
| FY2023 | — | $245.9M | $100.1M |
| FY2024 | — | $309.8M | $124.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $84.4M | $47.7M |
| FY2021 | — | $-42.9M | $48.3M |
| FY2022 | — | $-76.8M | $75.5M |
| FY2023 | — | $245.9M | $100.1M |
| FY2024 | — | $309.8M | $124.1M |